Previous close | 6.35 |
Open | 6.50 |
Bid | 6.70 x 12000 |
Ask | 7.05 x 12000 |
Day's range | 6.50 - 6.70 |
52-week range | 6.20 - 14.70 |
Volume | |
Avg. volume | 582 |
Market cap | 27.879B |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.75 |
Earnings date | N/A |
Forward dividend & yield | 0.03 (0.43%) |
Ex-dividend date | 29 Apr 2024 |
1y target est | 15.30 |
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
Bayer currently has more than twelve tiers between management and its customers in some departments, and the aim of CEO Bill Anderson is to reduce that to around five or six.
Chief executive Bill Anderson says he doesn’t want it to be a "lame" company, but its stock has still tanked 50%.